Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin’s lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of some adv...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2018-12-01
|
Series: | GE: Portuguese Journal of Gastroenterology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/494569 |
id |
doaj-a292260d2f6344ecaa3cf9c7ce1ae52c |
---|---|
record_format |
Article |
spelling |
doaj-a292260d2f6344ecaa3cf9c7ce1ae52c2020-11-25T03:34:15ZengKarger PublishersGE: Portuguese Journal of Gastroenterology2341-45452387-19542018-12-011710.1159/000494569494569Management of Gastrointestinal Toxicity from Immune Checkpoint InhibitorMarta RochaJoão Correia de SousaMarta SalgadoAntónio AraújoIsabel PedrotoImmune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin’s lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of some advanced malignancies, they are also associated with a significant risk of immune-related adverse events. These adverse events can occur in any organ system, but gastrointestinal side effects are among the most commonly reported, with manifestations ranging from mild diarrhoea to severe colitis, sharing some features with inflammatory bowel disease. Anticipating a greater use of these drugs in the future, gastroenterologists should expect to be increasingly faced with gastrointestinal immune-related adverse events. Knowledge of these toxicities, as well as effective management algorithms, is essential to enable early diagnosis and treatment, decreasing morbidity and mortality. We reviewed the currently available literature on gastrointestinal toxicity induced by immune checkpoint inhibitors, namely the clinical features, diagnosis, and management.https://www.karger.com/Article/FullText/494569Immune checkpoint inhibitorImmune-related adverse eventColitisDiarrhoea |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marta Rocha João Correia de Sousa Marta Salgado António Araújo Isabel Pedroto |
spellingShingle |
Marta Rocha João Correia de Sousa Marta Salgado António Araújo Isabel Pedroto Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor GE: Portuguese Journal of Gastroenterology Immune checkpoint inhibitor Immune-related adverse event Colitis Diarrhoea |
author_facet |
Marta Rocha João Correia de Sousa Marta Salgado António Araújo Isabel Pedroto |
author_sort |
Marta Rocha |
title |
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor |
title_short |
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor |
title_full |
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor |
title_fullStr |
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor |
title_full_unstemmed |
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor |
title_sort |
management of gastrointestinal toxicity from immune checkpoint inhibitor |
publisher |
Karger Publishers |
series |
GE: Portuguese Journal of Gastroenterology |
issn |
2341-4545 2387-1954 |
publishDate |
2018-12-01 |
description |
Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin’s lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of some advanced malignancies, they are also associated with a significant risk of immune-related adverse events. These adverse events can occur in any organ system, but gastrointestinal side effects are among the most commonly reported, with manifestations ranging from mild diarrhoea to severe colitis, sharing some features with inflammatory bowel disease. Anticipating a greater use of these drugs in the future, gastroenterologists should expect to be increasingly faced with gastrointestinal immune-related adverse events. Knowledge of these toxicities, as well as effective management algorithms, is essential to enable early diagnosis and treatment, decreasing morbidity and mortality. We reviewed the currently available literature on gastrointestinal toxicity induced by immune checkpoint inhibitors, namely the clinical features, diagnosis, and management. |
topic |
Immune checkpoint inhibitor Immune-related adverse event Colitis Diarrhoea |
url |
https://www.karger.com/Article/FullText/494569 |
work_keys_str_mv |
AT martarocha managementofgastrointestinaltoxicityfromimmunecheckpointinhibitor AT joaocorreiadesousa managementofgastrointestinaltoxicityfromimmunecheckpointinhibitor AT martasalgado managementofgastrointestinaltoxicityfromimmunecheckpointinhibitor AT antonioaraujo managementofgastrointestinaltoxicityfromimmunecheckpointinhibitor AT isabelpedroto managementofgastrointestinaltoxicityfromimmunecheckpointinhibitor |
_version_ |
1724559796516945920 |